• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

Canopy Growth Could Continue to Base Awhile but the Long-Term Looks Promising

Put CGC on your potential shopping list and let's keep an eye on it.
By BRUCE KAMICH
May 29, 2020 | 12:36 PM EDT
Stocks quotes in this article: CGC

Canopy Growth Corp. (CGC) is in the news today. They reported their fiscal Q4 results and also recorded impairment and restructuring charges of $743 million, the majority of which are non-cash charges. I will leave the fundamental analysis and numbers crunching to others but use this time to check on the charts and indicators.  

 
In this daily bar chart of CGC, below, we can see that prices are lower so far today but let's try to focus on the bigger picture. Yes, prices failed to decisively clear the declining 200-day moving average line, but they are still above the rising 50-day moving average line.
 
The daily trading volume or turnover has been pretty active since November and the daily On-Balance-Volume (OBV) line looks like it has bottomed since November with the start of more aggressive buying this month.
 
The trend-following Moving Average Convergence Divergence (MACD) oscillator moved above the zero line last month for an outright go long signal.  
 
 
In this weekly bar chart of CGC, below, we can see a number of positive developments. Prices are above the bottoming 40-week moving average line but today's close should put it below the line again.
 
The weekly OBV line has been rising since November and looks much more powerful than the daily OBV line. The MACD oscillator has turned up from a cover shorts buy signal and is heading back towards the zero line.  
 
 
 
In this first Point and Figure chart of CGC, below, we used percentage changes for the plotting and here the chart shows a downside price target in the $13-$12 area.  
 
 
 
In this second Point and Figure chart of CGC, below, we used the traditional even dollar increments for plotting and here this chart shows an upside price target in the $39-$40 area. The same data but a much different result.  
 
 
Bottom line strategy: CGC might experience some weakness in the short-run but the bigger picture, in my opinion, is that it has been bottoming since October. It is hard to say when the base will be complete and prices will launch a new uptrend but things are looking positive. Put CGC on your potential shopping list and let's keep an eye on it.  
Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are prohibited from trading individual securities.

TAGS: Investing | Stocks | Technical Analysis | Trading | Marijuana | Cannabis

More from Investing

Marveling at the Market's Move? It's All About Momentum

James "Rev Shark" DePorre
Jan 19, 2021 4:41 PM EST

No news can explain the action -- whether the bears believe it or not.

Surface Oncology Is Set for Further Gains - How to Buy It

Bruce Kamich
Jan 19, 2021 3:25 PM EST

Here's our price objective.

My Preference With OneSpan Is Calls So I Can Define My Risk

Timothy Collins
Jan 19, 2021 2:36 PM EST

The last few post-earnings beat downs were greeted with optimism once traders got over the initial disappointment.

A Top Biotechnology Play for 2021

James "Rev Shark" DePorre
Jan 19, 2021 2:07 PM EST

Forte's sole clinic candidate is FB-401 for the treatment of atopic dermatitis, which is the scientific name for eczema.

Boot Barn Gets a Quant Upgrade: Do the Charts Fit?

Bruce Kamich
Jan 19, 2021 1:53 PM EST

Here's our latest analysis and trading strategy for the shares.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:09 AM EST GARY BERMAN

    Is Copper About to Turn to Rust?

    Below is a very long-term copper chart.  As you...
  • 08:02 AM EST GARY BERMAN

    Tuesday Morning Fibocall for for 1/19/2021

    SPX (Long-Term View) The 1/8/21 high @ 3826.69 i...
  • 09:01 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    When it's time to sell, will you act or freeze?
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login